1.
Cardiovascular Toxicity of Nicotine: Implications for Electronic Cigarette Use
by Benowitz, Neal L
Trends in cardiovascular medicine, 2016, Vol.26 (6), p.515-523
2.
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
by Swedberg, Karl, Prof
The Lancet (British edition), 2010, Vol.376 (9744), p.875-885
3.
Computational fluid dynamics modelling in cardiovascular medicine
by Morris, Paul D
Heart, 2016-01, Vol.102 (1), p.18-28
4.
Medication adherence: A call for action
by Bosworth, Hayden B., PhD
The American heart journal, 2011, Vol.162 (3), p.412-424
5.
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiologica...
by Yusuf, Salim, Prof
The Lancet (British edition), 2011, Vol.378 (9798), p.1231-1243
6.
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
by Sabatine, Marc S., MD, MPH
The American heart journal, 2015, Vol.173, p.94-101
7.
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
by Böhm, Michael, Prof
The Lancet (British edition), 2010, Vol.376 (9744), p.886-894
8.
The epidemiology of cardiovascular disease in the UK 2014
by Bhatnagar, Prachi
Heart, 2015-08, Vol.101 (15), p.1182-1189
9.
Trends in the epidemiology of cardiovascular disease in the UK
by Bhatnagar, Prachi
Heart (British Cardiac Society), 2016-12, Vol.102 (24), p.1945-1952
10.
Sex differences in cardiovascular ageing
by Merz, Allison A
Heart, 2016-06, Vol.102 (11), p.825-831
11.
Metal pollutants and cardiovascular disease: Mechanisms and consequences of exposure
by Solenkova, Natalia V., MD, PhD
The American heart journal, 2014, Vol.168 (6), p.812-822
12.
Effects of geranylgeranylacetone upon cardiovascular diseases
by Zeng, Shengqiang
Cardiovascular therapeutics, 2018-08, Vol.36 (4), p.e12331-n/a
13.
FDA labeling of NSAIDs: Review of nonsteroidal anti-inflammatory drugs in cardiovascular disease
by Pirlamarla, Preethi, MD
Trends in cardiovascular medicine, 2016, Vol.26 (8), p.675-680
14.
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
by Holman, Rury R., FRCP, FMedSci
The American heart journal, 2016, Vol.174, p.103-110
15.
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
by Marso, Steven P., MD
The American heart journal, 2013, Vol.166 (5), p.823-830.e5
16.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODY...
by Kereiakes, Dean J., MD, FACC, FSCAI
The American heart journal, 2015, Vol.169 (6), p.906-915.e13
17.
Depression and cardiovascular disease
by Bradley, Steven M., MD, MPH
Trends in cardiovascular medicine, 2015, Vol.25 (7), p.614-622
18.
Lung function and cardiovascular disease: A link
by Ramalho, Sergio H.R
Trends in cardiovascular medicine, 2021-02, Vol.31 (2), p.93-98
19.
Endothelial to mesenchymal transition: A novel therapeutic target for cardiovascular diseases
by Jackson, Ampadu O
Trends in cardiovascular medicine, 2017, Vol.27 (6), p.383-393
20.
Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participan...
by Lorenz, Matthias W, Dr
The Lancet (British edition), 2012, Vol.379 (9831), p.2053-2062
